PMID 12654482
Results may vary from person to person depending on skin type, lifestyle, sun exposure, and treatment consistency
For patients with BMIs that started above 35, significant metabolic syndrome, or a history of yo-yo dieting, maintenance dosing often produces the best long-term outcomes
In the subpopulation of participants from the China region (75.2% of trial participants), reductions in HbA 1c and body weight from baseline to week 26 were similar to those seen in the overall population
Careful dose adjustment and monitoring are essential in clinical practice
This 30mg formulation is ideal for preclinical studies , particularly in the areas of diabetes , obesity , fat metabolism , and endocrine function